Your browser doesn't support javascript.
loading
An Enhancer-Driven Stem Cell-Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer.
Liang, Xiaoyan; Duronio, Gina N; Yang, Yaying; Bala, Pratyusha; Hebbar, Prajna; Spisak, Sandor; Sahgal, Pranshu; Singh, Harshabad; Zhang, Yanxi; Xie, Yingtian; Cejas, Paloma; Long, Henry W; Bass, Adam J; Sethi, Nilay S.
Afiliación
  • Liang X; Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Duronio GN; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Yang Y; Department of Pathology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, China.
  • Bala P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hebbar P; Department of Information Technology, National Institute of Technology Karnataka, Surathkal, India.
  • Spisak S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Sahgal P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
  • Singh H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Zhang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Xie Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Cejas P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bass AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts; Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine,
  • Sethi NS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts; Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine,
Gastroenterology ; 162(1): 209-222, 2022 01.
Article en En | MEDLINE | ID: mdl-34571027
ABSTRACT
BACKGROUND AND

AIMS:

Genomic alterations that encourage stem cell activity and hinder proper maturation are central to the development of colorectal cancer (CRC). Key molecular mediators that promote these malignant properties require further elucidation to galvanize translational advances. We therefore aimed to characterize a key factor that blocks intestinal differentiation, define its transcriptional and epigenetic program, and provide preclinical evidence for therapeutic targeting in CRC.

METHODS:

Intestinal tissue from transgenic mice and patients were analyzed by means of histopathology and immunostaining. Human CRC cells and neoplastic murine organoids were genetically manipulated for functional studies. Gene expression profiling was obtained through RNA sequencing. Histone modifications and transcription factor binding were determined with the use of chromatin immunoprecipitation sequencing.

RESULTS:

We demonstrate that SRY-box transcription factor 9 (SOX9) promotes CRC by activating a stem cell-like program that hinders intestinal differentiation. Intestinal adenomas and colorectal adenocarcinomas from mouse models and patients demonstrate ectopic and elevated expression of SOX9. Functional experiments indicate a requirement for SOX9 in human CRC cell lines and engineered neoplastic organoids. Disrupting SOX9 activity impairs primary CRC tumor growth by inducing intestinal differentiation. By binding to genome wide enhancers, SOX9 directly activates genes associated with Paneth and stem cell activity, including prominin 1 (PROM1). SOX9 up-regulates PROM1 via a Wnt-responsive intronic enhancer. A pentaspan transmembrane protein, PROM1 uses its first intracellular domain to support stem cell signaling, at least in part through SOX9, reinforcing a PROM1-SOX9 positive feedback loop.

CONCLUSIONS:

These studies establish SOX9 as a central regulator of an enhancer-driven stem cell-like program and carry important implications for developing therapeutics directed at overcoming differentiation defects in CRC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Neoplasias Colorrectales / Diferenciación Celular / Elementos de Facilitación Genéticos / Factor de Transcripción SOX9 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Gastroenterology Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Neoplasias Colorrectales / Diferenciación Celular / Elementos de Facilitación Genéticos / Factor de Transcripción SOX9 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Gastroenterology Año: 2022 Tipo del documento: Article